Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
View/ Open
Volume
386
Pagination
2059 - 2068
DOI
10.1016/S0140-6736(15)00257-3
Journal
LANCET
Issue
ISSN
0140-6736